Biotech Stock Soars 99% as Vertex Agrees to $10 Billion Takeover Deal
CRNX has more than doubled off its 52-week low of $25.83 on elevated volume (4.2× avg).
Summary
Crinetics Pharmaceuticals stock surged 99% to $83.69 after Vertex Pharmaceuticals agreed to acquire the company for $10 billion, or $85 per share in cash. This news confirms the market's strong positive reaction to the definitive agreement disclosed yesterday via SEC filings and news wires. The acquisition offers Crinetics shareholders a premium of over 100% from Monday's closing price, delivering immediate and substantial value. For Vertex, the deal is strategic, with expectations that Crinetics' key assets like PALSONIFY will contribute an additional $5 billion to annual revenue. The transaction is anticipated to close within the current quarter.
At the time of this announcement, CRNX was trading at $83.68 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.4B. The 52-week trading range was $25.83 to $57.99. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Dow Jones Newswires.